Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) has a beta value of -0.53 and has seen 0.46 million shares traded in the recent trading session. The company, currently valued at $311.88M, closed the recent trade at $3.52 per share which meant it lost -$0.02 on the day or -0.56% during that session. The AMLX stock price is -106.53% off its 52-week high price of $7.27 and 55.11% above the 52-week low of $1.58. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.66 million shares traded. The 3-month trading volume is 830.86K shares.
The consensus among analysts is that Amylyx Pharmaceuticals Inc (AMLX) is Buy stock at the moment, with a recommendation rating of 2.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 3 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.55.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Sporting -0.56% in the red today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the AMLX stock price touched $3.52 or saw a rise of 10.2%. Year-to-date, Amylyx Pharmaceuticals Inc shares have moved -6.88%, while the 5-day performance has seen it change -6.88%. Over the past 30 days, the shares of Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) have changed 17.33%. Short interest in the company has seen 3.75 million shares shorted with days to cover at 4.64.
Wall Street analysts have a consensus price target for the stock at $9, which means that the shares’ value could jump 60.89% from the levels at last check today. The projected low price target is $4.0 while the price target rests at a high of $11.0. In that case, then, we find that the latest price level in today’s session is -212.5% off the targeted high while a plunge would see the stock gain -13.64% from the levels at last check today.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
The company’s shares have gained 14.29% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -100.00%.
Year-ago sales stood 88.64M and -1.02M respectively for this quarter and the next, and analysts expect sales will shrink by -100.00% for the current quarter and -100.00% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -78.71% over the past 5 years. Earnings growth for 2025 is a modest 54.70% while over the next 5 years, the company’s earnings are expected to increase by 25.21%.
AMLX Dividends
Amylyx Pharmaceuticals Inc is expected to release its next earnings report on 2025-Mar-03 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s Major holders
Insiders own 11.70% of the company shares, while shares held by institutions stand at 65.66% with a share float percentage of 74.36%. Investors are also buoyed by the number of investors in a company, with Amylyx Pharmaceuticals Inc having a total of 162.0 institutions that hold shares in the company. The top two institutional holders are VANGUARD GROUP INC with over 4.22 million shares worth more than $8.03 million. As of 2024-06-30, VANGUARD GROUP INC held 6.2251% of shares outstanding.
The other major institutional holder is AQR CAPITAL MANAGEMENT LLC, with the holding of over 3.34 million shares as of 2024-06-30. The firm’s total holdings are worth over $6.35 million and represent 4.9114% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors. As of Dec 31, 2024, the former fund manager holds about 1.67% shares in the company for having 1.48 shares of worth $5.2 million while later fund manager owns 1.2 shares of worth $4.19 million as of Dec 31, 2024, which makes it owner of about 1.35% of company’s outstanding stock.
